Beijing Biostar Boosts Strategic Ties With Baheal via HK$100 Million Share Subscription

Beijing Biostar Pharmaceuticals Co., Ltd. Class H ( (HK:2563) ) just unveiled an announcement.

Beijing Biostar Pharmaceuticals has entered into a subscription agreement to issue 25,000,000 new shares at HK$4.00 each to a Hong Kong subsidiary of Qingdao Baheal Pharmaceutical, representing about 6.86% of its existing issued share capital. The subscriber, part of Shenzhen-listed Baheal Pharmaceutical, already holds a small stake in the company and is an independent third party under Hong Kong listing rules.

The deal deepens an existing strategic alliance between Biostar and Baheal, which already cooperate on marketing services and commercial distribution of Utidelone Injection. By bringing in additional equity from a partner focused on medical innovation and large-scale drug and equipment manufacturing, Biostar aims to reinforce collaboration in R&D, commercialization, and medical achievement transformation, potentially strengthening its market position and product pipeline execution.

More about Beijing Biostar Pharmaceuticals Co., Ltd. Class H

Beijing Biostar Pharmaceuticals Co., Ltd. is a PRC-incorporated biopharmaceutical company listed in Hong Kong, focused on developing and commercializing innovative medical products such as Utidelone Injection. It operates within China’s healthcare and pharmaceutical sector, leveraging strategic partnerships to advance R&D, industrialization of medical innovations, and commercialization across key therapeutic areas.

Average Trading Volume: 20,461

Technical Sentiment Signal: Hold

Current Market Cap: HK$1.64B

For an in-depth examination of 2563 stock, go to TipRanks’ Overview page.